Acute Coronary Syndrome Clinical Trials

Find Acute Coronary Syndrome Clinical Trials Near You

Guided Optimisation of Long-term Disease rEduction in secoNdary Prevention of CVD (GOLDEN). A Prospective Observational Study of Long-term Outcomes.

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

The goal of this observational study is to evaluate the implementation of a 'first-time-right' pharmacological treatment strategy in patients hospitalized with coronary artery disease. The main question it aims to answer is: Does early (immediately post-event) initiation of a full set of guideline-based, individualized, preventive medication lead to reductions in cardiovascular events compared to current practice (incremental titration strategies)? Researchers will compare the 'first-time-right' strategy group to the current practice group to see if there are improvements in major adverse cardiac and cerebrovascular events (MACE) at 36 months. Participants will: * Receive either the 'first-time-right' strategy or current practice for secondary prevention. * Be monitored (data collection) through routine clinical visits at baseline, 8 weeks, 12, and additional telephone contacts at 24, and 36 months after discharge. * Complete online questionnaires at hospitalization, 8 weeks, 12, 24, and 36 months after discharge.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• \>18 years of age (no upper limit)

• Coronary event, i.e. ACS or coronary revascularisation

• Able to provide informed consent

Locations
Other Locations
Netherlands
Amsterdam UMC
RECRUITING
Amsterdam
Contact Information
Primary
Manon van den Bogaart, drs.
m.vandenbogaart@amsterdamumc.nl
003120 5660703
Backup
Marjolein Snaterse, dr.
m.snaterse@amsterdamumc.nl
Time Frame
Start Date: 2024-07-09
Estimated Completion Date: 2029-01
Participants
Target number of participants: 5586
Treatments
'Current practice' group
The 'current practice' treated patients' group will provide data on current practices in the preventive treatment after hospitalization for acute coronary syndrome or coronary revascularization. (i.e. incremental, individual titration at treating physician's discretion)
'First-time-right' (FTR) group
In line with the 2021 ESC Prevention guidelines, the FTR group will be treated according to the 'first-time-right' strategy(1). While no specific therapeutic protocols are mandated by our observational study, participating centers will be required to apply the 'first-time- right' strategy: i.e. the direct, in-hospital initiation or planned initiation of all guideline-recommended preventive pharmacotherapeutic treatments.
Related Therapeutic Areas
Sponsors
Collaborators: Amarin Pharma Inc., Dutch Network for Cardiovascular Research (WCN), Utrecht, Novartis Pharmaceuticals
Leads: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

This content was sourced from clinicaltrials.gov